Aldebaran Capital’s PMV Pharmaceuticals PMVP Stock Holding History

Aldebaran Capital’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$626K	Sell	467,432 -5,930	-1%	-$7.61K	0.47%	29
2026 Q1	$587K	Sell	473,362 -4,626	-1%	-$5.88K	0.45%	31
2025 Q4	$597K	Sell	477,988 -26,140	-5%	-$35K	0.54%	25
2025 Q3	$706K	Sell	504,128 -11,000	-2%	-$15.2K	0.65%	23
2025 Q2	$546K	Sell	515,128 -8,425	-2%	-$8.26K	0.54%	25
2025 Q1	$571K	Buy	523,553 +21,363	+4%	+$29K	0.54%	26
2024 Q4	$758K	Buy	502,190 +63,938	+15%	+$101K	0.72%	26
2024 Q3	$653K	Buy	438,252 +87,009	+25%	+$134K	0.6%	27
2024 Q2	$569K	Buy	+351,243	New	+$633K	0.53%	26

Other funds holding PMVP

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Aldebaran Capital's PMVP Position: Q2 2026 in Review

Aldebaran Capital reduced its PMV Pharmaceuticals (PMVP) stake by 1.3% in Q2 2026, selling an estimated $7.61K and leaving 467,432 shares worth $626K. The position accounts for 0.47% of the portfolio, ranked #29.

Aldebaran Capital first reported a position in PMVP in Q2 2024 and has held it in 9 quarters since. The position peaked at $758K in Q4 2024. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

Aldebaran Capital held 467,432 shares of PMV Pharmaceuticals worth $626K as of Q2 2026.
Aldebaran Capital sold 5,930 PMV Pharmaceuticals shares in Q2 2026, an estimated $7.61K.
PMV Pharmaceuticals made up 0.47% of Aldebaran Capital's portfolio in Q2 2026, its #29 holding.
Aldebaran Capital first reported a position in PMV Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Aldebaran Capital's PMV Pharmaceuticals position peaked at $758K in Q4 2024.
64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Aldebaran Capital's 13F filing for Q2 2026, filed 14 Aug 2026.